



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: ☼ HIV-1 IIIB Virus

Catalog Number: 398

Lot Number: 170171

Release Category: C

Provided: 1 mL of cell-free virus
TCID₅₀ = 2.32 x 10⁵ TCID₅₀/mL in H9 cells
p24 = 410 ng/mL

Original Source: Human patient peripheral blood or bone marrow from patients with AIDS or related diseases.

Host Strain: H9 Cells

Propagation: Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20%; 1 X NEAA at 0.5-1 x 10⁶ cells/mL for optimum growth. Split 1:2-1:4 every 2-3 days.

Sterility: Negative for mycoplasma, bacteria, and fungi

Description: A group M, subtype B, HIV-1 virus isolate which utilizes CXCR4 co-receptor to infect cells.

Special Characteristics: Concentrated culture fluids of peripheral blood or bone marrow from several patients with AIDS or related diseases were used to establish a permanent productive infection in a cloned permissive neo-plastic T cell line (H9). HIV-1 IIIB Virus was then isolated from culture supernatant and cells showing cytopathic effect.

This virus has a high capacity to replicate in human T cell lines and appears to be well adapted for *in vitro* culture in T cells, however it replicates less well in fresh human macrophages. In addition to H9 cells, HIV-1 IIIB virus can also infect other human neo-plastic CD4⁺ T cells including CEM, U937, Molt 3, HeLa CD4⁺ cells, and human peripheral blood lymphocytes. This is a syncytia forming virus.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Alternative Name: HTLV-III B/ H9.

Recommended Storage:

Keep the reagent in liquid nitrogen.

Contributor:

Dr. Robert Gallo

References:

M. Popovic, E. Read-Connole and R. C. Gallo. (1984). T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. *Lancet*, 2(8417-8418), 1472-3. [PUBMED](#)

M. Popovic, M. G. Sarngadharan, E. Read and R. C. Gallo. (1984). Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science*, 224(4648), 497-500. [PUBMED](#)

L. Ratner, W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister and et al. (1985). Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature*, 313(6000), 277-84. [PUBMED](#)

S. Wain-Hobson, J. P. Vartanian, M. Henry, N. Chenciner, R. Cheynier, S. Delassus, L. P. Martins, M. Sala, M. T. Nugeyre, D. Guetard and et al. (1991). LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. *Science*, 252(5008), 961-5. [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB Virus from Dr. Robert Gallo (cat# 398)." Also include the references cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact the NCI Technology Transfer Center at the following email address: lauren.nguyen-antczak@nih.gov, before the reagent can be released.

Last Updated:

August 10, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.